Transmission prevention of viruses with application of antiseptic composition
Aspects of the present disclosure relate to a method of preventing transmission of an enveloped RNA virus. The method includes applying to a mucosal tissue of a first mammalian subject not substantially colonized by the enveloped RNA virus an effective amount of an antiseptic composition or a pharmaceutically acceptable salt thereof according to a treatment plan. The first mammalian subject not substantially colonized by the enveloped RNA virus interacts with a second mammalian subject colonized by the enveloped RNA virus at a first viral load, the first mammalian subject has a second viral load based on the interaction, the second viral load is no greater than 0.5 log increase over an initial viral load over a duration of the treatment plan. The mucosal tissue is in the nasopharynx, nasal cavity, or anterior nares of the mammalian subject. The antiseptic composition comprises iodine, iodophor, or combinations thereof.
1 . A method of preventing transmission of an enveloped RNA virus, comprising:
applying, to a mucosal tissue of a first mammalian subject not colonized by the enveloped RNA virus, an effective amount of an antiseptic composition or a pharmaceutically acceptable salt thereof according to a treatment plan, the treatment plan comprises a plurality of applications with more than 24 hours elapsed between each application;
allowing the first mammalian subject not colonized by the enveloped RNA virus to interact with a second mammalian subject colonized by the enveloped RNA virus at a first viral load, the first mammalian subject has a second viral load based on the interaction;
wherein the second viral load is no greater than 0.5 log increase over an initial viral load of the first mammalian subject over a duration of the treatment plan;
wherein the duration of the treatment plan is up to 24 hours before the interaction and up to 7 days after the interaction;
wherein the mucosal tissue is in a nasopharynx, nasal cavity, or anterior nares of the first mammalian subject;
wherein the antiseptic composition comprises:
greater than 5 wt-% hydroxycarboxylic acid;
0.25 wt-% to 1.5 wt-% amine oxide;
0.0045 wt-% to 0.55 wt-% available iodine concentration;
4.5 wt-% to 5.5 wt-% povidone-iodine;
a surfactant; and
water.
2 . The method of claim 1 , further comprising:
applying, to the mucosal tissue of the second mammalian subject colonized by the enveloped RNA virus at the first viral load, an effective amount of the antiseptic composition or the pharmaceutically acceptable salt thereof according to the treatment plan, wherein the mucosal tissue is in a nasopharynx, nasal cavity, or anterior nares of the second mammalian subject.
3 . The method of claim 1 , wherein not colonized by the enveloped RNA virus means that a viral concentration of the enveloped RNA virus is below a limit of detection for the enveloped RNA virus.
4 . The method of claim 1 , wherein not colonized by the enveloped RNA virus means that the first mammalian subject does not exhibit symptoms of the enveloped RNA virus.
5 . The method of claim 1 , wherein the first viral load is associated with onset of symptoms of the enveloped RNA virus.
6 . The method of claim 1 , wherein the first viral load is at least 1000 PFU per milliliter.
7 . The method of claim 1 , wherein the first viral load is at least 10000 PFU per milliliter.
8 . A method of preventing transmission of an enveloped RNA virus from a mammalian subject, comprising:
applying an effective amount of an antiseptic composition or a pharmaceutically acceptable salt of the antiseptic composition to a mucosal tissue of the mammalian subject having a first viral load for a duration of a treatment plan, wherein the mucosal tissue is in a nasopharynx, nasal cavity, or anterior nares of the mammalian subject and the duration of the treatment plan is up to 24 hours before the interaction and up to 7 days after the interaction;
allowing enveloped RNA virus to retain in the mucosal tissue from contact with the antiseptic composition;
wherein when a second mammalian subject that is not colonized by the enveloped RNA virus interacts with the mammalian subject, the mammalian subject does not transmit the enveloped RNA virus to the second mammalian subject during the duration of the treatment plan, the treatment plan comprises a plurality of applications with more than 24 hours elapsed between each application;
wherein the antiseptic composition comprises:
greater than 5 wt-% hydroxycarboxylic acid;
0.25 wt-% to 1.5 wt-% amine oxide;
0.0045 wt-% to 0.55 wt-% available iodine concentration;
4.5 wt-% to 5.5 wt-% povidone-iodine;
a surfactant; and
water.
9 . The method of claim 8 , wherein not colonized by the enveloped RNA virus means that a viral concentration of the enveloped RNA virus is below a limit of detection for the enveloped RNA virus.
10 . The method of claim 8 , wherein the first viral load is at least 1000 PFU per milliliter.
11 . A method of preventing transmission of a virus, comprising:
applying, to a mucosal tissue of a first mammalian subject colonized by a virus with a first viral load, an effective amount of an antiseptic composition or a pharmaceutically acceptable salt thereof according to a treatment plan, the treatment plan comprises a plurality of applications with more than 24 hours elapsed between each application; and
allowing a second mammalian subject colonized by the virus with a second viral load to interact with the first mammalian subject, the first mammalian subject has a third viral load based on the interaction;
wherein the third viral load is no greater than 0.5 log increase over the first viral load over a duration of the treatment plan, wherein the duration of the treatment plan is up to 24 hours before the interaction and up to 7 days after the interaction;
wherein the antiseptic composition comprises:
greater than 5 wt-% hydroxycarboxylic acid;
0.25 wt-% to 1.5 wt-% amine oxide;
0.0045 wt-% to 0.55 wt-% available iodine concentration;
4.5 wt-% to 5.5 wt-% povidone-iodine;
a surfactant; and
water.
12 . The method of claim 11 , wherein the first mammalian subject does not exhibit symptoms of the virus when colonized at the first viral load.
13 . The method of claim 11 , wherein the first viral load is no greater than 10 PFU per milliliter.
14 . The method of claim 11 , wherein the treatment plan occurs over a duration of 3 days.
15 . The method of claim 11 , further comprising applying, to a mucosal tissue of the second mammalian subject, an effective amount of the antiseptic composition or a pharmaceutically acceptable salt thereof according to the treatment plan, wherein the mucosal tissue is in a nasopharynx, nasal cavity, or anterior nares of the second mammalian subject.
16 . The method of claim 1 , wherein the antiseptic composition has a pH of less than 4.
17 . The method of claim 1 , wherein applying the effective amount of the antiseptic composition to the first mammalian subject comprises first applying the antiseptic composition at least 24 hours after interaction with the second mammalian subject.
18 . The method of claim 1 , wherein the antiseptic composition comprises a vehicle, the vehicle comprises water and a polyethylene glycol having a weight average molecular weight of less than 1500.